Bruker Launches D8 VENTURE BIOTOOLS For Home Laboratory

Headquartered in Billerica, MA, Bruker Corporation (NASDAQ:BRKR) is focusing on strengthening its position in the growing scientific instruments market. In line with this, the company recently announced D8 VENTURE BIOTOOLS for laboratory macromolecular crystallography. This will be part of the Bruker AXS segment within Bruker Nano.

The D8 VENTURE BIOTOOLS has a few latest features in terms of source, detector and sample handling technology. As per the company, it features the new ImS DIAMOND (IµS DIAMOND), the brightest microfocus X-ray source. Also, IµS DIAMOND can run continuously without any routine maintenance. Bruker also offers 99% uptime guarantee with this new technology.

Further, the latest version of Excillum METALJET is a powerful alternative to the compact, microfocus IµS DIAMOND.

According to Bruker, D8 VENTURE BIOTOOLS features the new PHOTON III, the largest photon-counting pixel array detector for the home laboratory.

As per the company, the new SCOUT automated cryo-cooled crystal-handling system features a ceiling-mounted robot for sampling handling and state-of-the-art cryogenic technology. SCOUT incorporates the new AGH automated goniometer head. The AGH allows samples to be aligned automatically with X-rays.

Management believes that D8 VENTURE BIOTOOLS has enabled the company to set new standards in crystallography systems for the home laboratory. According to a report by Markets and Markets, the protein crystallization market is estimated to see a CAGR of 10.1% to reach a worldwide market of $1,253 million by 2018.

One of the recent developments in the Bruker Nano segment is the launch of the next-generation Wavelength Dispersive X-Ray Fluorescence (WDXRF) spectrometer, S8 TIGER Series 2. This is a versatile WDXRF tool available for advanced quantitative elemental analysis in industrial and academic materials research along with industrial quality control (QC) of materials.

In the last three reported quarters, the Bruker Nano business saw profits from the prior restructuring and cost actions. In the last reported second quarter, solid growth was driven by contributions from Hysitron nanoindenting product's acquisition in late January and improved results at the AXS business.

Bruker has been trading above the broader industry over the last three months. During this period, the stock has generated a positive return of 5.3%, higher than the 1.3% gain of the broader industry.

Zacks Rank & Key Picks

Bruker currently carries a Zacks Rank 3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corp. (NYSE:EW) , Lantheus Holdings, Inc. (NASDAQ:LNTH) and Stryker Corporation (NYSE:SYK) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and Stryker carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 19.4% over the last six months.

Stryker has a long-term expected earnings growth rate of 10.00%. The stock has rallied roughly 12.8% over the last six months.

Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has gained 28.6% over the last six months.

Zacks' 10-Minute Stock-Picking Secret

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.

Learn the secret >>